Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Acute myocardial infarction? 252 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 252 reports of Acute myocardial infarction have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.1% of all adverse event reports for ADALIMUMAB.

252
Reports of Acute myocardial infarction with ADALIMUMAB
0.1%
of all ADALIMUMAB reports
78
Deaths
158
Hospitalizations

How Dangerous Is Acute myocardial infarction From ADALIMUMAB?

Of the 252 reports, 78 (31.0%) resulted in death, 158 (62.7%) required hospitalization, and 37 (14.7%) were considered life-threatening.

Is Acute myocardial infarction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 252 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Acute myocardial infarction?

ROSIGLITAZONE (2,437) TESTOSTERONE (871) ASPIRIN (826) CLOPIDOGREL BISULFATE (624) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (521) TICAGRELOR (442) RIVAROXABAN (375) METFORMIN (370) LENALIDOMIDE (354) METFORMIN\ROSIGLITAZONE (351)

Which ADALIMUMAB Alternatives Have Lower Acute myocardial infarction Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Acute myocardial infarction Reports All Drugs Causing Acute myocardial infarction ADALIMUMAB Demographics